Biodistribution and cumulative survival of leukemic mice treated with anti-mCD45 Ab-SA. (A) Biodistribution of radioactivity in blood, marrow, spleen, and normal organs of leukemic SJL/J mice injected with ¹²⁵I-anti-mCD45 Ab-SA on day 2 post-AML inoculation. Leukemic mice were injected via the tail vein with 0.67 nmol of conventional trace-labeled ¹²⁵I-anti-mCD45 Ab-SA or ¹²⁵I-IgG Ab-SA at time = 0 hours and killed 8 hours later. The radioactivity in blood, marrow, and spleen was quantified by gamma counting, corrected for decay, and expressed as percent ID/g of tissue. Error bars are SD. (B) Analysis of cumulative survival of SJL/J mice inoculated with myeloid leukemia treated with PRIT using anti-mCD45 Ab-SA conjugate. Groups of 5 mice harboring murine leukemia were treated as described in the legend to Figure 4 and analyzed for survival as a function of time. Treatment groups included mice treated with 0.67 nmol of anti-mCD45 Ab-SA or control IgG-SA conjugate, mice that did not receive any Ab-SA conjugate, or control untreated mice, followed 8 hours later by 100, 200, or 300 μCi of ⁹⁰Y-DOTA-biotin.